Diabetes mellitus secondary to endocrine diseases: a position statement of the working group of the club of the Italian society of endocrinology (SIE)-Nutrition hormones and metabolism
Authors:
- 28 April 2025
- journal article
- consensus statement
- Published by Springer Nature in Journal of Endocrinological Investigation
- Vol. 48 (8) , 1739-1758
Abstract
Purpose This position statement addressed the limited scientific literature on the management of diabetes mellitus secondary to endocrinopathies, despite its frequent occurrence in hormonal diseases such as acromegaly, Cushing’s syndrome, primary hyperaldosteronism, pheochromocytoma, hyperthyroidism, and neuroendocrine tumors. The aim was to review the pathophysiological mechanisms, clinical features, and management strategies, focusing on nutritional and pharmacological approaches. Methods A comprehensive review of existing literature was conducted regarding studies on diabetes secondary to endocrinopathies and the effects of treatments for these conditions, such as somatostatin analogues and pancreatic surgery. Particular emphasis was placed on understanding glucose metabolism derangements and the interplay between endocrine excess and therapeutic interventions. Results Secondary diabetes arises not only from hormone excess but also as a consequence of treatments for endocrine disorders. For instance, somatostatin analogues, while effective in resolving hormone hypersecretion, impair glucose metabolism by inhibiting pancreatic insulin secretion. Similarly, pancreatic surgery for neuroendocrine tumors often exacerbates glycemic disturbances. The management of secondary diabetes requires a multidisciplinary approach that includes treating the underlying endocrine disorder, tailoring antidiabetic therapy, and optimizing nutritional strategies to mitigate metabolic disruptions. Conclusion Diabetes secondary to endocrinopathies presents unique challenges due to its complex etiology and the metabolic effects of treatments. This position statement underscores the importance of an integrated management approach, offering guidance for clinicians in addressing this multifaceted condition. Further research is needed to develop evidence-based guidelines for optimal care.Keywords
This publication has 214 references indexed in Scilit:
- Cushing SyndromeJAMA, 2023
- 2023 update on Italian guidelines for the treatment of type 2 diabetesActa Diabetologica, 2023
- Diabetes mellitus induced by somatostatin analogue therapy is not permanent in acromegalic patientsEndocrinology, Diabetes & Metabolism, 2018
- Impact of Adrenal Steroids on Regulation of Adipose TissueComprehensive Physiology, 2017
- Aldosterone decreases glucose-stimulated insulin secretion in vivo in mice and in murine isletsDiabetologia, 2011
- The impact of diet and micronutrient supplements on the expression of neuroendocrine markers in murine Lady transgenic prostateThe Prostate, 2008
- IGF-1 receptor signalling determines the mitogenic potency of insulin analogues in human smooth muscle cells and fibroblastsDiabetologia, 2007
- Involvement of ?1 and ?-adrenoceptors in adrenaline stimulation of the glucagon-secreting mouse ?-cellNaunyn-Schmiedeberg's Archives of Pharmacology, 2004
- Glucagonomas/diabetico-dermatogenic syndrome (DDS): A statistical evaluation of 407 reported casesJournal of Hepato-Biliary-Pancreatic Surgery, 1998
- Bromocriptine treatment over 12 years in acromegaly: effect on glucose tolerance and insulin secretionJournal of Molecular Medicine, 1993